Update on intravesical agents for non-muscle-invasive bladder cancer

Immunotherapy

Volumn 2, Issue 3, 2010, Pages 381-392

  Shariat, Shahrokh F ^a,b   Chade, Daher C ^a   Karakiewicz, Pierre I ^c   Scherr, Douglas S ^b   Dalbagni, Guido ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^b WEILL CORNELL MEDICAL COLLEGE   (United States)

^c UNIVERSITÉ DE MONTRÉAL   (Canada)

Author keywords

Administration; Antineoplastic agent; Chemotherapy; Immunotherapy; Intravesical; Local; Mycobacterium bovis; Neoplasm recurrence; Urinary bladder neoplasm

Indexed keywords

BCG VACCINE; DOCETAXEL; DOXORUBICIN; EPIRUBICIN; GEMCITABINE; MITOMYCIN C; THIOTEPA;

ALLERGIC REACTION; ANTINEOPLASTIC ACTIVITY; BLADDER CANCER; CANCER CHEMOTHERAPY; CANCER GROWTH; CANCER IMMUNOTHERAPY; CANCER INVASION; CANCER RECURRENCE; CARCINOMA IN SITU; CLINICAL TRIAL; CYSTECTOMY; CYSTITIS; DOSE RESPONSE; DRUG EFFICACY; DRUG FATALITY; DRUG FEVER; DRUG HYPERSENSITIVITY; DRUG WITHDRAWAL; DYSURIA; HEMATURIA; HOSPITAL INFECTION; HUMAN; IMMUNOPROPHYLAXIS; INFECTION; INFLAMMATION; MAINTENANCE THERAPY; MALAISE; METASTASIS; MULTIPLE CYCLE TREATMENT; NONHUMAN; ORCHITIS; PAPILLOMA; PRIORITY JOURNAL; PROSTATITIS; PRURITUS; RECURRENT CANCER; REVIEW; RUBOR; SEPSIS; SKIN MANIFESTATION; TRANSURETHRAL RESECTION; TREATMENT FAILURE; TREATMENT RESPONSE; UNSPECIFIED SIDE EFFECT; URINARY TRACT INFECTION;

ADMINISTRATION, INTRAVESICAL; ANTINEOPLASTIC AGENTS; BCG VACCINE; COMBINED MODALITY THERAPY; CYSTECTOMY; HUMANS; MITOMYCIN; TAXOIDS; TREATMENT OUTCOME; URINARY BLADDER NEOPLASMS;

EID: 77953455162     PISSN: 1750743X     EISSN: None     Source Type: Journal    
DOI: 10.2217/imt.10.1     Document Type: Review

References (82)

1. Parkin DM: The global burden of urinary bladder cancer. Scand. J. Urol. Nephrol. Suppl. 218, 12-20 (2008).
2. Kirkali Z, Chan T, Manoharan M et al.: Bladder cancer: epidemiology, staging and grading, and diagnosis. Urology 66, 4-34 (2005).
3. Sylvester RJ: Natural history, recurrence, and progression in superficial bladder cancer. Scientific W. J. 6, 2617-2625 (2006).
4. Lotan Y, Capitanio U, Shariat SF, Hutterer GC, Karakiewicz PI: Impact of clinical factors, including a point-of-care nuclear matrix protein-22 assay and cytology, on bladder cancer detection. BJU Int. 103, 1368-1374 (2009).
5. Lotan Y, Bensalah K, Ruddell T, Shariat SF, Sagalowsky AI, Ashfaq R: Prospective evaluation of the clinical usefulness of reflex fluorescence in situ hybridization assay in patients with atypical cytology for the detection of urothelial carcinoma of the bladder. J. Urol. 179, 2164-2169 (2008).
6. Karakiewicz PI, Benayoun S, Zippe C et al.: Institutional variability in the accuracy of urinary cytology for predicting recurrence of transitional cell carcinoma of the bladder. BJU Int. 97, 997-1001 (2006).
7. Shariat, SF, Casella R, Wians FH Jr et al.: Risk stratification for bladder tumor recurrence, stage and grade by urinary nuclear matrix protein 22 and cytology. Eur. Urol. 45, 304-313; author reply 313 (2004).
8. Pawinski A, Sylvester R, Kurth KH et al.: A combined analysis of European Organization for Research and Treatment of Cancer, and Medical Research Council randomized clinical trials for the prophylactic treatment of stage TaT1 bladder cancer. European Organization for Research and Treatment of Cancer Genitourinary Tract Cancer Cooperative Group and the Medical Research Council Working Party on Superficial Bladder Cancer. J. Urol. 156, 1934-1940; discussion 1940-1941 (1996).
9. Shariat SF, Zippe C, Ludecke G et al.: Nomograms including nuclear matrix protein 22 for prediction of disease recurrence and progression in patients with Ta, T1 or CIS transitional cell carcinoma of the bladder. J. Urol. 173, 1518-1525 (2005).
10. Crispen R: History of BCG and its substrains. Prog. Clin. Biol. Res. 310, 35-50 (1989).
11. Mathe, G, Amiel JL, Schwarzenberg L et al.: Active immunotherapy for acute lymphoblastic leukaemia. Lancet 1, 697-699 (1969).
12. Morton D, Eilber FR, Malmgren RA, Wood WC: Immunological factors which influence response to immunotherapy in malignant melanoma. Surgery 68, 158-163; discussion 163-164 (1970).
13. Zbar B, Bernstein ID, GL Bartlett, Hanna MG Jr, Rapp HJ: Immunotherapy of cancer: regression of intradermal tumors and prevention of growth of lymph node metastases after intralesional injection of living Mycobacterium bovis. J. Natl Cancer. Inst. 49, 119-130 (1972).
14. Coe JE, Feldman JD: Extracutaneous delayed hypersensitivity, particularly in the guinea-pig bladder. Immunology 10, 127-136 (1966).
15. Morales A, Eidinger D, Bruce AW: Intracavitary bacillus Calmette-Guerin in the treatment of superficial bladder tumors. J. Urol. 116, 180-183 (1976).
16. Lamm DL: Bacillus Calmette-Guerin immunotherapy for bladder cancer. J. Urol. 134, 40-47 (1985).
17. Mori K, Lamm DL, Crawford ED: A trial of bacillus Calmette-Guerin versus adriamycin in superficial bladder cancer: a South-West Oncology Group study. Urol. Int. 41, 254-259 (1986). (Pubitemid 17175303)
18. Herr HW, Pinsky CM, Whitmore Jr. WF , Oettgen HF, Melamed MR: Effect of intravesical bacillus Calmette-Guerin (BCG) on carcinoma in situ of the bladder. Cancer 51, 1323-1326 (1983).
19. Herr HW, Pinsky CM, Whitmore Jr. WF , Sogani PG, Oettgen HF, Melamed MR: Experience with intravesical bacillus Calmette-Guerin therapy of superficial bladder tumors. Urology 25, 119-123 (1985).
20. Yoneyama T, Ohyama C, Imai A et al.: Low-dose instillation therapy with bacille Calmette-Guerin Tokyo 172 strain after transurethral resection: historical cohort study. Urology 71, 1161-1165 (2008).
21. Sylvester RJ, van der MA, Lamm DL: Intravesical bacillus Calmette-Guerin reduces the risk of progression in patients with superficial bladder cancer: a meta-analysis of the published results of randomized clinical trials. J. Urol. 168, 1964-1970 (2002).
22. Martinez-Pineiro JA, Martinez-Pineiro L, Solsona E et al.: Has a 3-fold decreased dose of bacillus Calmette-Guerin the same efficacy against recurrences and progression of T1G3 and Tis bladder tumors than the standard dose? Results of a prospective randomized trial. J. Urol. 174, 1242-1247 (2005).
23. Zlotta AR, van Vooren JP, Huygen K et al.: What is the optimal regimen for BCG intravesical therapy? Are six weekly instillations necessary? Eur. Urol. 37, 470-477 (2000).
24. de Boer EC, Rooyakkers SJ, Schamhart DH, de Reijke TM, Kurth KH: BCG dose reduction by decreasing the instillation frequency: effects on local Th1/Th2 cytokine responses in a mouse model. Eur. Urol. 48, 333-338 (2005).
25. Melekos MD, Chionis H, Pantazakos A, Fokaefs E, Paranychianakis G, Dauaher H: Intravesical bacillus Calmette-Guerin immunoprophylaxis of superficial bladder cancer: results of a controlled prospective trial with modified treatment schedule. J. Urol. 149, 744-748 (1993).
26. Krege S, Giani G, Meyer R, Otto T, Rubben H: A randomized multicenter trial of adjuvant therapy in superficial bladder cancer: transurethral resection only versus transurethral resection plus mitomycin C versus transurethral resection plus bacillus Calmette-Guerin. Participating clinics. J. Urol. 156, 962-966 (1996).
27. Iantorno R, Nicolai M, Mastroprimiano G et al.: Randomized prospective study comparing long-term intravesical instillation of BCG after transurethral resection and transurethral resection alone in patients with superficial bladder cancer. J. Urol. 161(Suppl.), 284 (1999).
28. Lamm DL: Long-term results of intravesical therapy for superficial bladder cancer. Urol. Clin. N. Am. 19, 573-580 (1992).
29. Millan-Rodriguez, F, Chechile-Toniolo G, Salvador-Bayarri J, Palou J, Vicente-Rodriguez J: Multivariate analysis of the prognostic factors of primary superficial bladder cancer. J. Urol. 163, 73-78 (2000).
30. Shelley MD, Court JB, Kynaston H, Wilt TJ, Fish RG, Mason M: Intravesical bacillus Calmette-Guerin in Ta and T1 bladder cancer. Cochrane Database Syst. Rev. CD001986 (2000).
31. Witjes JA, Fransen MP, van der Meijden AP, Doesburg WH, Debruyne FM: Use of maintenance intravesical bacillus Calmette- Guerin (BCG), with or without intradermal BCG, in patients with recurrent superficial bladder cancer. Long-term follow-up of a randomized phase 2 study. Urol. Int. 51, 67-72 (1993).
32. Han RF, Pan JG: Can intravesical bacillus Calmette-Guerin reduce recurrence in patients with superficial bladder cancer? A meta-analysis of randomized trials. Urology 67, 1216-1223 (2006).
33. Joudi FN, Smith BJ, O'Donnell MA: Final results from a national multicenter Phase II trial of combination bacillus Calmette-Guerin plus interferon a-2B for reducing recurrence of superficial bladder cancer. Urol. Oncol. 24, 344-348 (2006).
34. Herr HW, Donat SM, Dalbagni G: Can restaging transurethral resection of T1 bladder cancer select patients for immediate cystectomy? J. Urol. 177, 75-79; discussion 79 (2007).
35. Hudson MA, Ratliff TL, Gillen DP et al.: Single course versus maintenance bacillus Calmette-Guerin therapy for superficial bladder tumors: a prospective, randomized trial. J. Urol. 138, 295-298 (1987).
36. Badalament RA, Herr HW, Wong GY et al.: A prospective randomized trial of maintenance versus nonmaintenance intravesical bacillus Calmette-Guerin therapy of superficial bladder cancer. J. Clin. Oncol. 5, 441-449 (1987).
37. Palou J, Laguna P, Millan-Rodriguez F, Hall RR et al.: Control group and maintenance treatment with bacillus Calmette-Guerin for carcinoma in situ and/or high grade bladder tumors. J. Urol. 165, 1488-1491 (2001).
38. Lamm DL, Blumenstein BA, Crissman JD et al.: Maintenance bacillus Calmette-Guerin immunotherapy for recurrent Ta, T1 and carcinoma in situ transitional cell carcinoma of the bladder: a randomized Southwest Oncology Group Study. J. Urol. 163, 1124-1129 (2000).
39. Böhle A, Jocham D, Bock PR: Intravesical bacillus Calmette-Guerin versus mitomycin C for superficial bladder cancer: a formal meta-analysis of comparative studies on recurrence and toxicity. J. Urol. 169, 90-95 (2003).
40. Malmström PU, Sylvester RJ, Crawford DE et al.: An individual patient data meta-analysis of the long-term outcome of randomised studies comparing intravesical mitomycin C versus bacillus Calmette- Guerin for non-muscle-invasive bladder cancer. Eur. Urol. 56, 247-256 (2009).
41. Herr HW: Is maintenance bacillus Calmette-Guerin really necessary? Eur. Urol. 54, 971-973 (2008).
42. Sylvester RJ, van der Meijden AP, Witjes JA, Kurth K: Bacillus Calmette-Guerin versus chemotherapy for the intravesical treatment of patients with carcinoma in situ of the bladder: a meta-analysis of the published results of randomized clinical trials. J. Urol. 174, 86-91; discussion 91-92 (2005).
43. Orihuela E, Herr HW, Pinsky CM, Whitmore Jr. WF : Toxicity of intravesical BCG and its management in patients with superficial bladder tumors. Cancer 60, 326-333 (1987).
44. Berry DL, Blumenstein BA, Magyary DL, Lamm DL, Crawford ED: Local toxicity patterns associated with intravesical bacillus Calmette-Guerin: a Southwest Oncology Group study. Int J. Urol. 3, 98-100; discussion 101 (1996).
45. Shoenfeld Y, Aron-Maor A, Tanai A, Ehrenfeld M: BCG and autoimmunity: another two-edged sword. J. Autoimmun. 16, 235-240 (2001).
46. van der Meijden AP, Sylvester RJ, Oosterlinck W, Hoeltl W, Bono AV: Maintenance bacillus Calmette-Guerin for Ta T1 bladder tumors is not associated with increased toxicity: results from a European Organisation for Research and Treatment of Cancer Genito-Urinary Group Phase III trial. Eur. Urol. 44, 429-434 (2003). (Pubitemid 37185667)
47. Rischmann P, Desgrandchamps F, Malavaud B, Chopin DK: BCG intravesical instillations: recommendations for side-effects management. Eur. Urol. 37(Suppl. 1), 33-36 (2000).
48. Koya MP, Simon MA, Soloway MS: Complications of intravesical therapy for urothelial cancer of the bladder. J. Urol. 175, 2004-2010 (2006).
49. Malmstrom PU, Wijkstrom H, Lundholm C, Wester K, Busch C, Norlen BJ: 5-year followup of a randomized prospective study comparing mitomycin C and bacillus Calmette-Guerin in patients with superficial bladder carcinoma. Swedish-Norwegian Bladder Cancer Study Group. J. Urol. 161, 1124-1127 (1999).
50. Bilen CY, Inci K, Erkan I, Ozen H: The predictive value of purified protein derivative results on complications and prognosis in patients with bladder cancer treated with bacillus Calmette-Guerin. J. Urol. 169, 1702-1705 (2003).
51. DeVeale B, Brummel T, Seroude L: Immunity and aging: the enemy within? Aging Cell 3, 195-208 (2004).
52. Heiner JG, Terris MK: Effect of advanced age on the development of complications from intravesical bacillus Calmette-Guerin therapy. Urol. Oncol. 26, 137-140 (2008).
53. Nilsson S, Ragnhammar P, Glimelius B, Nygren P: A systematic overview of chemotherapy effects in urothelial bladder cancer. Acta Oncol. 40, 371-390 (2001). (Pubitemid 32588129)
54. Thrasher JB, Crawford ED: Complications of intravesical chemotherapy. Urol. Clin. North Am. 19, 529-539 (1992).
55. Gao X, Au JL, Badalament RA, Wientjes MG: Bladder tissue uptake of mitomycin C during intravesical therapy is linear with drug concentration in urine. Clin. Can. Res. 4, 139-143 (1998).
56. Au JL, Badalament RA, Wientjes MG et al.: Methods to improve efficacy of intravesical mitomycin C: results of a randomized Phase III trial. J. Natl Cancer Instit. 93, 597-604 (2001).
57. Huncharek M, Geschwind JF, Witherspoon B, McGarry R, Adcock D: Intravesical chemotherapy prophylaxis in primary superficial bladder cancer: a meta-analysis of 3703 patients from 11 randomized trials. J. Clin. Epidemiol. 53, 676-680 (2000).
58. Huncharek M, McGarry R, Kupelnick B: Impact of intravesical chemotherapy on recurrence rate of recurrent superficial transitional cell carcinoma of the bladder: results of a meta-analysis. Anticancer Res. 21, 765-769 (2001).
59. Lamm DL, Riggs DR, Traynelis CL, Nseyo UO: Apparent failure of current intravesical chemotherapy prophylaxis to influence the long-term course of superficial transitional cell carcinoma of the bladder. J. Urol. 153, 1444-1450 (1995).
60. Sylvester RJ, Oosterlinck W, van der Meijden AP: A single immediate postoperative instillation of chemotherapy decreases the risk of recurrence in patients with stage Ta T1 bladder cancer: a meta-analysis of published results of randomized clinical trials. J. Urol. 171, 2186-2190; quiz 2435 (2004).
61. Dalbagni G, Russo P, Sheinfeld J et al.: Phase I trial of intravesical gemcitabine in bacillus Calmette-Guerin-refractory transitional-cell carcinoma of the bladder. J. Clin. Oncol. 20, 3193-3198 (2002).
62. Dalbagni G, Russo P, Bochner B et al.: Phase II trial of intravesical gemcitabine in bacille Calmette-Guerin-refractory transitional cell carcinoma of the bladder. J. Clin. Oncol. 24, 2729-2734 (2006).
63. Laufer M, Ramalingam S, Schoenberg MP et al.: Intravesical gemcitabine therapy for superficial transitional cell carcinoma of the bladder: a Phase I and pharmacokinetic study. J. Clin. Oncol. 21, 697-703 (2003).
64. De Berardinis E, Antonini G, Peters GJ et al.: Intravesical administration of gemcitabine in superficial bladder cancer: a Phase I study with pharmacodynamic evaluation. BJU Int. 93, 491-494 (2004).
65. McKiernan JM, Masson P, Murphy AM et al.: Phase I trial of intravesical docetaxel in the management of superficial bladder cancer refractory to standard intravesical therapy. J. Clin. Oncol. 24, 3075-3080 (2006).
66. Laudano MA, Barlow LJ, Murphy AM et al.: Long-term clinical outcomes of a Phase I trial of intravesical docetaxel in the management of non-muscle-invasive bladder cancer refractory to standard intravesical therapy. Urology 75(1), 134-137 (2009).
67. Lamm DL, Blumenstein BA, Crawford ED et al.: A randomized trial of intravesical doxorubicin and immunotherapy with bacille Calmette-Guerin for transitional-cell carcinoma of the bladder. N. Engl. J. Med. 325, 1205-1209 (1991).
68. Shelley MD, Wilt TJ, Court J et al.: Intravesical bacillus Calmette-Guerin is superior to mitomycin C in reducing tumour recurrence in high-risk superficial bladder cancer: a meta-analysis of randomized trials. BJU Int. 93, 485-490 (2004).
69. Hall MC, Chang SS, Dalbagni G et al.: Guideline for the management of nonmuscle invasive bladder cancer (stages Ta, T1, and Tis): 2007 update. J. Urol. 178, 2314-2330 (2007).
70. Ojea A, Nogueira JL, Solsona E et al.: A multicentre, randomised prospective trial comparing three intravesical adjuvant therapies for intermediate-risk superficial bladder cancer: low-dose bacillus Calmette-Guerin (27 mg) versus very low-dose bacillus Calmette-Guerin (13.5 mg) versus mitomycin C. Eur. Urol. 52, 1398-1406 (2007).
71. Friedrich MG, Pichlmeier U, Schwaibold H, Conrad S, Huland H: Long-term intravesical adjuvant chemotherapy further reduces recurrence rate compared with short-term intravesical chemotherapy and short-term therapy with bacillus Calmette-Guerin (BCG) in patients with non-muscle-invasive bladder carcinoma. Eur. Urol. 52, 1123-1129 (2007).
72. Böhle A, Bock PR: Intravesical bacille Calmette-Guerin versus mitomycin C in superficial bladder cancer: formal meta-analysis of comparative studies on tumor progression. Urology 63, 682-686; discussion 686-687 (2004).
73. Huncharek M, Kupelnick B: The influence of intravesical therapy on progression of superficial transitional cell carcinoma of the bladder: a metaanalytic comparison of chemotherapy versus bacilli Calmette-Guerin immunotherapy. Am. J. Clin. Oncol. 27, 522-528 (2004).
74. Huland H, Kloppel G, Feddersen I et al.: Comparison of different schedules of cytostatic intravesical instillations in patients with superficial bladder carcinoma: final evaluation of a prospective multicenter study with 419 patients. J. Urol. 144, 68-71; discussion 71-72 (1990).
75. Bouffioux C, Kurth KH, Bono A et al.: Intravesical adjuvant chemotherapy for superficial transitional cell bladder carcinoma: results of 2 European Organization for Research and Treatment of Cancer randomized trials with mitomycin C and doxorubicin comparing early versus delayed instillations and short-term versus long-term treatment. European Organization for Research and Treatment of Cancer Genitourinary Group. J. Urol. 153, 934-941 (1995).
76. Okamura K, Kinukawa T, Tsumura Y et al.: A randomized study of short-versus long-term intravesical epirubicin instillation for superficial bladder cancer. Nagoya University Urological Oncology Group. Eur. Urol. 33, 285-288; discussion 289 (1998).
77. Koga H, Kuroiwa K, Yamaguchi A, Osada Y, Tsuneyoshi M, Naito S: A randomized controlled trial of short-term versus long-term prophylactic intravesical instillation chemotherapy for recurrence after transurethral resection of Ta/T1 transitional cell carcinoma of the bladder. J. Urol. 171, 153-157 (2004).
78. Conrad S, Friedrich MG, Schwaibold H: Long term prophylaxis with mitomycin C (MMC) further reduces tumor recurrence compared with short term prophylaxis with MMC or bacillus Calmette-Guerin (BCG). J. Urol. 171, 271 (2004).
79. Cookson MS, Herr HW, Zhang ZF, Soloway S, Sogani PC, Fair WR: The treated natural history of high risk superficial bladder cancer: 15-year outcome. J. Urol. 158, 62-67 (1997).
80. Herr HW, Dalbagni G: Defining bacillus Calmette-Guerin refractory superficial bladder tumors. J. Urol. 169, 1706-1708 (2003).
81. Luo Y, Chen X, O'Donnell MA: Role of Th1 and Th2 cytokines in BCG-induced IFN-g production: cytokine promotion and simulation of BCG effect. Cytokine 21, 17-26 (2003).
82. Morales A, Phadke K, Steinhoff G: Intravesical mycobacterial cell wall-DNA complex in the treatment of carcinoma in situ of the bladder after standard intravesical therapy has failed. J. Urol. 181, 1040-1045 (2009).